Lipid lowering with inclisiran: a real-world single-centre experience

Area of Science:

• Cardiology
• Pharmacology
• Lipid Metabolism

Background:

• Reducing low-density lipoprotein cholesterol (LDL-c) is crucial for managing atherosclerotic cardiovascular disease.
• Inclisiran is a novel lipid-lowering agent demonstrating efficacy in clinical trials.
• Real-world data on inclisiran's early effects are limited.

Purpose of the Study:

• To analyze the early impact of inclisiran on lipid profiles in a real-world clinical setting.
• To assess the effectiveness and tolerability of inclisiran in a tertiary lipid clinic.
• To evaluate changes in LDL-c, total cholesterol, HDL-c, and triglycerides post-inclisiran treatment.

Main Methods:

• Retrospective analysis of the first 80 patients receiving inclisiran.
• Data collected from electronic healthcare records at a tertiary lipid and cardiovascular risk clinic.
• Lipid profiles and adverse events assessed at baseline and 2-month follow-up.

Main Results:

• Mean LDL-c decreased by 48.6% (p<0.0001) from 3.5 to 1.8 mmol/L.
• Total cholesterol reduced by 33.3% (p<0.0001); HDL-c increased by 7.7% (p=0.02).
• Triglycerides fell by 31.3% (p=0.001); three patients reported self-limiting adverse events.

Conclusions:

• Inclisiran significantly lowers LDL-c within two months in a real-world setting.
• Treatment aligns with NICE guidelines and shows efficacy comparable to clinical trials.
• Inclisiran demonstrates good tolerability and effectiveness in managing lipid levels.